Table 1.
Characteristics of the Case Patients and Control Subjects
| Characteristic a | Case Patients (no. [%]) | Control Subjects (no. [%]) | P |
| Age at study entry, years | .44 | ||
| 18–24 | 42 (67.7) | 111 (73.0) | |
| ≥25 | 20 (32.3) | 41 (27.0) | |
| Raceb | .25 | ||
| White | 44 (72.1) | 97 (63.8) | |
| Nonwhite | 17 (27.9) | 55 (36.2) | |
| Lifetime no. of male sex partnersc | .99 | ||
| 0–5 | 32 (52.5) | 79 (52.3) | |
| ≥6 | 29 (47.5) | 72 (47.7) | |
| Current hormonal contraceptive used | .23 | ||
| No | 37 (59.7) | 75 (50.7) | |
| Yes | 25 (40.3) | 73 (49.3) | |
| Smoking status | <.001 | ||
| Never | 16 (25.8) | 85 (55.9) | |
| Current | 34 (54.8) | 52 (34.2) | |
| Former | 12 (19.4) | 15 (9.9) | |
| No. of Pap tests/year in the past 5 years | .95 | ||
| <1 | 36 (58.1) | 89 (58.6) | |
| ≥1 | 26 (41.9) | 63 (41.4) | |
| Coinfection with other high-risk HPV types | .61 | ||
| No | 27 (43.5) | 72 (47.4) | |
| Yes | 35 (56.5) | 80 (52.6) | |
| Cytologic findings | <.001 | ||
| Within normal limits | 8 (12.9) | 77 (50.7) | |
| ASCUS | 13 (21.0) | 38 (25.0) | |
| SIL | 41 (66.1) | 37 (24.3) | |
| Study arm | .82 | ||
| Immediate colposcopy | 19 (30.6) | 46 (30.3) | |
| HPV triage | 7 (11.3) | 22 (14.5) | |
| Conservative management | 36 (58.1) | 84 (55.2) | |
| Follow-up visit no. for viral load analysis | .37 | ||
| 1 | 17 (27.4) | 58 (38.2) | |
| 2 | 19 (30.7) | 35 (23.0) | |
| 3 | 10 (16.1) | 28 (18.4) | |
| 4 | 16 (25.8) | 31 (20.4) |
NOTE. a Characteristics were based on information at enrollment, with the exceptions of coinfection with other high-risk HPV types and cytologic findings, which were based on information at follow-up visits where HPV-16 DNA load was measured.
b
One case patient who did not provide information on race was excluded. The category of “Nonwhite” race includes African American, American Indian/Alaskan, and Asian/Pacific Islander women.
c
One case patient and one control subject who did not provide information on lifetime number of male sex partners were excluded.
d
Four control subjects who did not provide information on hormonal contraceptive use were excluded.